Joey Med

September 2, 2026

1. 1. None of the three weight-loss plan pages ever name a specific active ingredient in their visible text — 'GLP-1 Core', 'GLP-1 Plus Core', and 'GLP-1 Plus Core High Dose' are all described only as generic 'GLP-1' with weekly injections, so all three are recorded as 'unspecified GLP-1' rather than assigned to semaglutide or tirzepatide. Notably the third plan's own URL slug is /weight-loss/tirz-hd (apparently short for 'tirzepatide high dose'), which strongly implies the drug, but per the brief's rule that a fact must appear in the printed page text, the URL alone was not treated as confirmation — the page body itself never says 'tirzepatide.' Each plan's pricing line reads 'Choose weeks/plan $[higher] / $[lower]' without stating whether the lower number is a monthly price, a one-time introductory price, or price-per-a-specific-number-of-weeks (the phrase 'Choose weeks/plan' suggests a week-count selector whose exact terms aren't resolved in static text) — recorded at term:1 as the closest reading but flagged as uncertain. Prescriber model is explicitly disclosed as either synchronous or asynchronous depending on the encounter, a rare direct answer. State coverage is asserted broadly as all 50 states in both the page title and body copy.